ZNF217 and breast cancer: Littlepage et al. [38] demonstrated that the AKT signaling pathway was downstream of ZNF217, and that triciribine, which is a pharmacological inhibitor of AKT activation, attenuated the growth of breast cancer in xenografted mice models expressing high ZNF217.